NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the former National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). This research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide, with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

About NRG Oncology Clinical Trial GU006

NRG-GU006 is a clinical trial that studies the effects, both positive and negative, of adding a new hormone suppression drug apalutamide to the usual radiotherapy treatment for patients who have had surgery to remove their prostate, but still had their prostate cancer return. Apalutamide is an FDA approved drug for patients with more advanced prostate cancer, and is being investigated now in this trial for men with recurrent prostate cancer after surgery. However, it may be beneficial in shrinking your cancer or preventing it from returning. Apalutamide may also cause side effects.

NRG-GU006 will allow researchers to know whether this different treatment approach is better, the same, or worse than the usual approach to your type of prostate cancer.

Contact Information

NRG Oncology
Four Penn Center
1600 JFK Blvd., Suite 1020
Philadelphia, PA 19103
(215) 854-0716
info@nrgoncology.org

Does apalutamide along with radiotherapy improve outcomes for patients with recurrent prostate cancer?
What is a clinical trial?
Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
Patients who have prostate cancer and had surgery to remove their prostate but their PSA level (a measure of prostate cancer) shows that their cancer has returned. Your doctor can determine if you meet these requirements.

Am I required to be in this study?
No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?
NRG-GU006 has two study groups. Group 1 will receive the usual radiotherapy used for this type of cancer plus a placebo (a pill that looks like the study drug, but contains no medication). Group 2 will receive the usual radiotherapy used for this type of cancer plus the study drug, apalutamide.

How long will I be in this study?
You will receive the usual radiation for 7 to 8 weeks. You will start taking the study drug/placebo when you start radiation therapy. You will receive radiotherapy for 7-8 weeks and take a placebo or apalutamide daily for 6 months. To monitor the response to your treatment, you will have usual follow-up appointments with your doctor.

Are there side effects?
For patients taking apalutamide, possible risks include fatigue, skin rash, joint pain, weight loss, fall, fractures, and other less common side effects. For patients receiving prostate radiation, possible risks include the need to urinate more frequently, more urgency with urination, or slower urinary flow, as well as pain with urination and/or bowel movements. Other risks include hair loss in the treatment area, tiredness, abnormal sexual function that may be permanent, and more. Your doctor will review all of the potential side effects with you.

More Information
You may visit the NCI website at cancer.gov for more information about studies or general information about cancer.
You may also call the NCI Cancer Information Service to get the same information at 1-(800)-4-CANCER (1-800-422-6237)